It has been predicted that patients with moderate to severe rheumatoid arthritis will see low disease activity after being treated with certolizumab pegol.
This low disease activity was found to occur in week 28, with the findings coming as part of clinical research by UCB entitled RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol (REALISTIC).
Professor Desiree van der Heijde from Leiden University Medical Centre, said: "For many patients living with moderate to severe rheumatoid arthritis, especially those with a long standing disease history, low disease activity is an appropriate alternative to remission."
The expert went on to say that data from the analysis found that low disease activity is dependent on the timing and magnitude of an initial clinical response to ertolizumab pegol.
These studies are only one of the many that are currently ongoing at UCB, which is currently making a series of presentations at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin.